SARC-CalF Score Calculator for Sarcopenia

Clinical calculation support · Verify results before clinical use

SARC-CalF Assessment

Complete the five SARC-F questions and enter the patient's calf circumference.

—Total score
1

Strength

How much difficulty do you have in lifting and carrying 10 pounds (approximately 4.5 kg)?

0–2 points
2

Assistance with Walking

How much difficulty do you have walking across a room?

0–2 points
3

Rise from a Chair

How much difficulty do you have transferring from a chair or bed?

0–2 points
4

Climb Stairs

How much difficulty do you have climbing a flight of 10 stairs?

0–2 points
5

Falls

How many times have you fallen in the past year?

0–2 points
6

Calf Circumference

Measure the maximum circumference of the calf using a non-elastic tape. Use the larger measurement from either leg.

0 or 10 points
Select sex to display the applicable AWGS 2019 threshold.

About the SARC-CalF Score

SARC-CalF combines the five-item SARC-F questionnaire with calf circumference to support case-finding for sarcopenia. The SARC-F domains are strength, assistance with walking, rising from a chair, climbing stairs, and falls. Each domain contributes 0–2 points (maximum SARC-F score: 10).

For this calculator, the calf circumference component follows the Asian Working Group for Sarcopenia (AWGS) 2019 thresholds: 10 additional points for circumference below 34 cm in men or below 33 cm in women. The total SARC-CalF score ranges from 0 to 20.

Scoring

ComponentCriterionPoints
StrengthNone / Some / A lot or unable0 / 1 / 2
Assistance walkingNone / Some / A lot, aids, or unable0 / 1 / 2
Rise from chairNone / Some / A lot or unable without help0 / 1 / 2
Climb stairsNone / Some / A lot or unable0 / 1 / 2
FallsNone / 1–3 / ≥4 in the past year0 / 1 / 2
Calf circumferenceMale <34 cm; female <33 cm10 if below threshold; otherwise 0

Interpretation (AWGS 2019)

Total scoreScreening interpretation
0–10Below SARC-CalF threshold; calf circumference or SARC-F may still independently trigger case-finding
11–20SARC-CalF screen positive; further assessment recommended

Measurement note

Measure the widest point of the calf with a non-elastic tape. AWGS 2019 specifies the maximum value of both calves. Keep the tape snug without compressing the soft tissue, and use a consistent measurement technique.

Evidence and limitations

An Indonesian cross-sectional evaluation in 266 adults aged 60 years or older reported an AUC of 0.572, sensitivity of 19.35%, and specificity of 95.0% for SARC-CalF at the recommended threshold. The authors cautioned that the recommended screening cutoffs may not perform consistently in the Indonesian population. A positive result should prompt assessment, while a negative result should not override clinical suspicion.

References

Chen LK, Woo J, Assantachai P, et al. Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. J Am Med Dir Assoc. 2020;21(3):300–307.e2. DOI: 10.1016/j.jamda.2019.12.012.
Malmstrom TK, Miller DK, Simonsick EM, Ferrucci L, Morley JE. SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes. J Cachexia Sarcopenia Muscle. 2016;7(1):28–36. DOI: 10.1002/jcsm.12048.
Kandinata SG, Widajanti N, Ichwani J, Firdausi H, Aryana IGPS, Alkaff FF. Diagnostic performance of calf circumference, SARC-F, and SARC-CalF for possible sarcopenia screening in Indonesia. Scientific Reports. 2023;13:9824. DOI: 10.1038/s41598-023-36585-4. Indonesian population evidence evaluating AWGS 2019 screening thresholds.
EWGSOP2 consensus (supporting context). Cruz-Jentoft AJ, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16–31. DOI: 10.1093/ageing/afy169.
Clinical disclaimer: SARC-CalF is a screening and case-finding instrument, not a confirmatory diagnostic test. Follow-up assessment should use the applicable regional consensus pathway and may include muscle strength, physical performance, and muscle quantity assessment. Interpret results in the context of the patient's clinical condition, comorbidities, mobility, and measurement limitations.